Weekly Roundup 24 Nov 2023 Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA …will go towards the development of Alto’s central nervous system (CNS) candidates. This will be done through placebo-controlled clinical trials that are set to end in 2025. Investment was led… November 24, 2023 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Opinion 25 Oct 2023 Microbiome: are we ready for third generation live biotherapeutics? …(GI) infections and conditions, to boosting the potency of immuno-oncology treatments and perhaps in the future, the treatment of central nervous system (CNS) and metabolic diseases. It’s not been an… October 25, 2023 - 11 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 12 Feb 2018 No Nonsense Boehringer Ingelheim Jettisons Failing Alzheimer’s Disease Drug …once the results of the study are fully understood at the upcoming Alzheimer’s Association International Conference in July, though. Jan Poth, head of CNS diseases at Boehringer, appears to have… February 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 24 Jan 2024 A new chapter in cell therapy: engineered B cells reach the clinic for the first time …therapeutics have application – from lysosomal storage diseases to obesity/diabetes, CNS disorders, oncology, and beyond,” commented Ainsworth. Ainsworth also explained that one of the main benefits of engineered B cells… January 24, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Dec 2023 Seven companies shaping the future of precision medicine …company Alto Neuroscience secured $45 million in a series C funding round last month, which it will use to support the clinical development of its central nervous system (CNS) candidates…. December 14, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2025 Psychedelics sans side effects: neuroplastogens gain ground …central nervous system (CNS) engagement. Preclinical data demonstrated that DLX-001 increased dendritic spine density in the neurons in the prefrontal cortex, the region located at the front of the frontal… June 27, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Expert Advice 15 Jan 2020 How to Spot a Biotech Winner: Investment Lessons from Sofinnova …have been created on RNA editing. There will be an IP battle, I suspect, not unlike CRISPR has seen. There’s this permanent pendulum. As you know, CNS was completely off…. January 15, 2020 - 10 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 Aug 2023 Six Toronto-based biotech companies to watch this year …like Deep Genomics having developed a portfolio of candidates, some of which are being evaluated as therapies for central nervous system (CNS)-related disorders, the city’s research and development sector is… August 17, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 And We’re Off! First Patient Dosed in this Spanish Biotech’s Rare Disease Trial …that don’t have a donor. This leaves the door open for Minoryx to target adrenomyeloneuropathy with MIN-102, as well as other CNS indications going forward. The company has come a… January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 3 Apr 2018 Seven Expert Tips on How to Grow a Successful Biotech Startup …ago and has just started communicating to the world his goal of treating CNS disorders using RNA technology. “That becomes a whole paradigm shift,” says de Vlaam. “From having everyone… April 3, 2018 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 12 Jul 2023 Medicon Valley: how the initiative shaped biotech ecosystems in Denmark and Sweden …including diabetes, central nervous system (CNS) diseases and the microbiome. Medicon Village: connecting Sweden’s life science ecosystem While Medicon Valley Alliance pursues binational development in life sciences, Medicon Village, which… July 12, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Oct 2017 Buongiorno Biotech! Top 4 Companies Making Milan Europe’s Next Biotech Hub …managed to get its Parkinson’s drug approved earlier this year. In doing this, it became one of the first biotechs in the EU with an approved CNS drug. Xadago tackles… October 10, 2017 - 7 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email